Moleculin Biotech wins Mexican patent for lung-targeted liposomal Annamycin through 2040 - MBRX News | RalliesMoleculin Biotech wins Mexican patent for lung-targeted liposomal Annamycin through 2040
M
MBRX• Mexican patent extends exclusivity for Annamycin technology
- Moleculin Biotech won a Mexican patent covering its lung-targeted liposomal formulation of Annamycin.
- The protection runs through Nov. 23, 2040, extending exclusivity for the technology in Mexico.
- Annamycin is being evaluated in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia.
QNME
•
